
|Articles|June 1, 2001
- Pharmaceutical Executive-06-01-2001
- Volume 0
- Issue 0
Rx-to-OTC: Unwanted Attention
Author(s)Kevin Gopal
Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.
Advertisement
Articles in this issue
about 25 years ago
Industry Under Investigationabout 25 years ago
Emotion - The New Brand Integratorabout 25 years ago
For Love of the Gameabout 25 years ago
Field of Dreamsabout 25 years ago
Workshop: Access Optionsabout 25 years ago
Emotion - The New Brand Integratorabout 25 years ago
Emotion - Biotech Renaissance Manabout 25 years ago
Relocation: Coming to Americaabout 25 years ago
Stocks: Catching the Market Bluesabout 25 years ago
Gathering LightAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The New Healthy Aging Imperative and What It Means for Pharma
2
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
3
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
4
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
5




